Metro Holdings takes 10% stake in Hyphens Pharma subsidiary DocMed at $60 mil valuation

The Edge Singapore
The Edge Singapore5/27/2022 11:13 AM GMT+08  • 2 min read
Metro Holdings takes 10% stake in Hyphens Pharma subsidiary DocMed at $60 mil valuation
From left: Timothy Chen, Yip Hoong Mun, Lim See Wah / Photo: Hyphens Pharma International
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Property and retail company Metro Holdings is investing $6 million for a 10% stake in digital health platform DocMed Technology, valuing this subsidiary of Hyphens Pharma International at $60 million.

As part of the transaction, Hyphens Pharma will be conducting a restructuring exercise to transfer its shareholding of Pan-Malayan Pharmaceuticals to be a wholly-owned subsidiary of DocMed. The enlarged entity is headed by Timothy Chen.

Upon completion of the transaction, Hyphens Pharma will see its interest in DocMed diluted from 100% to 89.76%, or worth $53.86 million based on Metro’s investment. Besides Metro's 10%, the remaining 0.24% is held by Chen, who has signalled his commitment by taking this stake for $100,000. Hyphens Pharma has a market value of just over $88 million.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now